CardioSert

CardioSert develops tools designed to support interventional cardiologists in percutaneous coronary intervention (PCI) procedures. The companys products include a proprietary guide wire designed for crossing complex lesions, such as chronic total occlusion (CTO), and a pressure guide wire for measuring fractional flow reserve (FFR). CardioSerts CTO tool enables the physician to gently maneuver within the microchannels that pass throughout the arterial blockage. The tool follows the microchannels in order to pass the blockage safely and quickly, allowing the delivery of balloon/stent catheters to the desired location within the blockage. The companys FFR tool acts as an off-the-shelf workhorse guide wire and is equipped with a means for sensing the level of artery recanalization or assessing the level of artery blockage pre-operation, providing the physician with an important clinical decision-making tool. CardioSerts CTO tool was licensed by Microbot Medical Inc in 2018. In May 2019, Microbot acquired a novel patent-protected technology from CardioSert and now owns CardioSerts innovative technology, including R&D information, technical know-how, and intellectual property.

CardioSert was founded in 2012 by Avrahan Shkalim (Co-founder & CEO), Noam Peleg (Co-founder & CTO).

CardioSert operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Sensing. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

CardioSert is based in HaShoshanim Street 24, Nesher, Israel, North District.